Literature DB >> 26820580

Assessment of cortical damage in early multiple sclerosis with quantitative T2 relaxometry.

René-Maxime Gracien1,2, Sarah C Reitz1,2, Stephanie-Michelle Hof1,2, Vinzenz Fleischer3,4, Hilga Zimmermann3,4, Amgad Droby3,4, Helmuth Steinmetz1, Frauke Zipp3,4, Ralf Deichmann2, Johannes C Klein1,2.   

Abstract

T2 relaxation time is a quantitative MRI in vivo surrogate of cerebral tissue damage in multiple sclerosis (MS) patients. Cortical T2 prolongation is a known feature in later disease stages, but has not been demonstrated in the cortical normal appearing gray matter (NAGM) in early MS. This study centers on the quantitative evaluation of the tissue parameter T2 in cortical NAGM in a collective of early MS and clinically isolated syndrome (CIS) patients, hypothesizing that T2 prolongation is already present at early disease stages and variable over space, in line with global and focal inflammatory processes in MS. Additionally, magnetization transfer ratio (MTR) mapping was performed for further characterization of the expected cortical T2 alteration. Quantitative T2 and MTR maps were acquired from 12 patients with CIS and early MS, and 12 matched healthy controls. The lesion-free part of the cortical volume was identified, and the mean T2 and MTR values and their standard deviations within the cortical volume were determined. For evaluation of spatial specificity, cortical lobar subregions were tested separately for differences of mean T2 and T2 standard deviation. We detected significantly prolonged T2 in cortical NAGM in patients. T2 prolongation was found across the whole cerebral cortex and in all individual lobar subregions. Significantly higher standard deviations across the respective region of interest were found for the whole cerebral cortex and all subregions, suggesting the occurrence of spatially inhomogeneous cortical damage in all regions studied. A trend was observed for MTR reduction and increased MTR variability across the whole cortex in the MS group, suggesting demyelination. In conclusion, our results suggest that cortical damage in early MS is evidenced by spatially inhomogeneous T2 prolongation which goes beyond demyelination. Iron deposition, which is known to decrease T2, seems less prominent.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  MTR; T2; cerebral cortex; multiple sclerosis (MS); normal appearing gray matter (NAGM); quantitative MRI (qMRI)

Mesh:

Year:  2016        PMID: 26820580     DOI: 10.1002/nbm.3486

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  15 in total

1.  Cortical quantitative MRI parameters are related to the cognitive status in patients with relapsing-remitting multiple sclerosis.

Authors:  Alexandra van Wijnen; Franca Petrov; Michelle Maiworm; Stefan Frisch; Christian Foerch; Elke Hattingen; Helmuth Steinmetz; Johannes C Klein; Ralf Deichmann; Marlies Wagner; René-Maxime Gracien
Journal:  Eur Radiol       Date:  2019-10-10       Impact factor: 5.315

2.  Potential clinical impact of multiparametric quantitative MR spectroscopy in neurological disorders: A review and analysis.

Authors:  Ivan I Kirov; Assaf Tal
Journal:  Magn Reson Med       Date:  2019-08-08       Impact factor: 4.668

3.  Longitudinal assessment of early-life white matter development with quantitative relaxometry in nonhuman primates.

Authors:  Jason F Moody; Nakul Aggarwal; Douglas C Dean; Do P M Tromp; Steve R Kecskemeti; Jonathan A Oler; Ned H Kalin; Andrew L Alexander
Journal:  Neuroimage       Date:  2022-02-10       Impact factor: 6.556

4.  Rapid quantification of global brain volumetry and relaxometry in patients with multiple sclerosis using synthetic magnetic resonance imaging.

Authors:  Jibin Cao; Xiaohan Xu; Jingyi Zhu; Puyeh Wu; Huize Pang; Guoguang Fan; Lingling Cui
Journal:  Quant Imaging Med Surg       Date:  2022-06

5.  ISGylation is induced in neurons by demyelination driving ISG15-dependent microglial activation.

Authors:  Benjamin D S Clarkson; Ethan Grund; Kenneth David; Renee K Johnson; Charles L Howe
Journal:  J Neuroinflammation       Date:  2022-10-20       Impact factor: 9.587

6.  Comparison of two quantitative proton density mapping methods in multiple sclerosis.

Authors:  René-Maxime Gracien; Sarah C Reitz; Marlies Wagner; Christoph Mayer; Steffen Volz; Stephanie-Michelle Hof; Vinzenz Fleischer; Amgad Droby; Helmuth Steinmetz; Sergiu Groppa; Elke Hattingen; Johannes C Klein; Ralf Deichmann
Journal:  MAGMA       Date:  2016-08-20       Impact factor: 2.310

7.  Whole brain 3D MR fingerprinting in multiple sclerosis: a pilot study.

Authors:  Thomaz R Mostardeiro; Ananya Panda; Norbert G Campeau; Robert J Witte; Nicholas B Larson; Yi Sui; Aiming Lu; Kiaran P McGee
Journal:  BMC Med Imaging       Date:  2021-05-22       Impact factor: 1.930

8.  Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis.

Authors:  Cristina Granziera; Jens Wuerfel; Frederik Barkhof; Massimiliano Calabrese; Nicola De Stefano; Christian Enzinger; Nikos Evangelou; Massimo Filippi; Jeroen J G Geurts; Daniel S Reich; Maria A Rocca; Stefan Ropele; Àlex Rovira; Pascal Sati; Ahmed T Toosy; Hugo Vrenken; Claudia A M Gandini Wheeler-Kingshott; Ludwig Kappos
Journal:  Brain       Date:  2021-06-22       Impact factor: 13.501

9.  Quantitative measurement of macromolecular tissue properties in white and gray matter in healthy aging and amnestic MCI.

Authors:  Elveda Gozdas; Hannah Fingerhut; Hua Wu; Jennifer L Bruno; Lauren Dacorro; Booil Jo; Ruth O'Hara; Allan L Reiss; S M Hadi Hosseini
Journal:  Neuroimage       Date:  2021-05-15       Impact factor: 7.400

10.  The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis.

Authors:  René-Maxime Gracien; Alina Jurcoane; Marlies Wagner; Sarah C Reitz; Christoph Mayer; Steffen Volz; Stephanie-Michelle Hof; Vinzenz Fleischer; Amgad Droby; Helmuth Steinmetz; Frauke Zipp; Elke Hattingen; Ralf Deichmann; Johannes C Klein
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.